Biocon Biologics Limited, a subsidiary of Biocon Ltd., has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management). This recognition highlights the company's exceptional IP value creation and leadership in the region. This marks the ninth consecutive year that Biocon and Biocon Biologics have been featured on this prestigious list, first earning a spot in 2016 as the inaugural Indian pharmaceutical company to achieve this distinction. The award was presented during IPBC Asia in Tokyo from November 18-20, 2025. Shreehas Tambe, CEO & Managing Director, Biocon Biologics, stated that this recognition reflects their sustained commitment to innovation and a strong intellectual property strategy, reinforcing their stature as a global biosimilars leader and the role of IP in expanding patient access to high-quality, affordable therapies worldwide.